Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

Video

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms (MPNs).

In recent years, cellular therapy has evolved rapidly in lymphoid malignancies, especially in lymphoma and ​multiple myeloma, says Mesa.

Notably, at the Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Paul ​J. Shaughnessy, MD, of Methodist Hospital, expanded on these data and provided insight on future directions of CAR T-cell therapy ​in hematologic malignancies.

The utility of cellular-based therapy, in both hematologic and non-hematologic malignancies, has sparked great interest ​across oncology. Encouraging data suggest CAR T-cell therapy may soon find a place in the MPNs space, ​concludes Mesa.

Recent Videos
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
© 2025 MJH Life Sciences

All rights reserved.